Telotristat Etiprate for Carcinoid Syndrome Therapy (TELECAST)
The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome
Actual Study Start Date: March 11, 2014
Actual Primary Completion Date: March 29, 2016
Actual Study Completion Date: March 29, 2016
Arm:
- Experimental: 250 mg Telotristat Etiprate
- Experimental: 500 mg Telotristat Etiprate
- Placebo Comparator: Placebo
Related journal:
- Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Category | Value |
---|---|
Date last updated at source | 2018-02-26 |
Study type(s) | Interventional |
Expected enrolment | 76 |
Study start date | 2014-03-11 |
Estimated primary completion date | 2016-03-29 |